Article
A novel NR3C2 polymorphism and the increased thyroid-stimulating hormone concentration are associated with venlafaxine treatment outcome in Chinese Han MDD patients.
Psychiatry research - 1 Feb 2020
Yuan Fan, Yuan Ruixue, Ren Decheng, Bi Yan, Niu Weibo, Guo Zhenming, Wu Xi, Xu Fei, Sun Qianqian, Ma Gaini, Yang Fengping, Zhu Yuhao, Yu Tao, Li Xingwang, He Lin, Shi Lei, He Guang
Abstract excerpt
OBJECTIVE: We aimed to study the association among venlafaxine antidepressive outcome, NR3C2 gene polymorphisms and the change of two neuroendocrine hormones during treatment. METHODS: 195 Chinese Han major depressive disorder (MDD) patients were recruited and received a 6-week venlafaxine treatment in this study. Adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH) levels were measured at the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
